MX2011012629A - Inhibidores de actividad de cinasa tipo pirimidina. - Google Patents

Inhibidores de actividad de cinasa tipo pirimidina.

Info

Publication number
MX2011012629A
MX2011012629A MX2011012629A MX2011012629A MX2011012629A MX 2011012629 A MX2011012629 A MX 2011012629A MX 2011012629 A MX2011012629 A MX 2011012629A MX 2011012629 A MX2011012629 A MX 2011012629A MX 2011012629 A MX2011012629 A MX 2011012629A
Authority
MX
Mexico
Prior art keywords
sup
kinase activity
compounds
pyrimidine inhibitors
pyrimidine
Prior art date
Application number
MX2011012629A
Other languages
English (en)
Inventor
Scott A Erickson
George S Sheppard
Jieyi Wang
Steve D Fidanze
Gary T Wang
Bryan K Sorensen
Richard F Clark
Randy L Bell
Robert A Mantei
Nwe Y Ba-Maung
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2011012629A publication Critical patent/MX2011012629A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente solicitud se describen compuestos de la fórmula (I) o sales o solvatos farmacéuticamente aceptables de los mismos, en la cual G1, L1, R2, R3, n, p, Ar1, y Ar2 se definen en la descripción. También se describen métodos para elaborar dichos compuestos, y composiciones que comprenden dichos compuestos los cuales son útiles para inhibir cinasas tales como IGF-IR.
MX2011012629A 2009-05-27 2010-05-26 Inhibidores de actividad de cinasa tipo pirimidina. MX2011012629A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18155509P 2009-05-27 2009-05-27
PCT/US2010/036184 WO2010138575A1 (en) 2009-05-27 2010-05-26 Pyrimidine inhibitors of kinase activity

Publications (1)

Publication Number Publication Date
MX2011012629A true MX2011012629A (es) 2012-03-06

Family

ID=42352237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012629A MX2011012629A (es) 2009-05-27 2010-05-26 Inhibidores de actividad de cinasa tipo pirimidina.

Country Status (8)

Country Link
US (1) US8536180B2 (es)
EP (1) EP2435435B1 (es)
JP (1) JP2012528174A (es)
CN (1) CN102459265A (es)
CA (1) CA2763624A1 (es)
ES (1) ES2453097T3 (es)
MX (1) MX2011012629A (es)
WO (1) WO2010138575A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
DK2575968T3 (en) 2010-06-01 2016-05-30 Summit Therapeutics Plc COMPOUNDS FOR THE TREATMENT OF Clostridium difficile-associated disease
GB2480815A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EP3039015B1 (en) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
EP4045506A4 (en) * 2019-10-15 2023-08-30 Aucentra Therapeutics Pty Ltd 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL)PYRIMIDINE-2-AMINE DERIVATIVES FOR TREATMENT OF PROLIFERATIVE DISEASES AND CONDITIONS
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
HUP0400323A2 (hu) * 2001-03-28 2005-11-28 Bristol-Myers Squibb Company Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
EP1382603B1 (en) * 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006504755A (ja) * 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
AU2005205118B2 (en) * 2004-01-09 2009-02-26 Novartis Ag Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors
EP1828185B1 (en) * 2004-12-21 2009-05-06 SmithKline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
US20080242667A1 (en) * 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
WO2007031745A1 (en) * 2005-09-16 2007-03-22 Astrazeneca Ab Pyrimidine derivatives for the inhibition of igf-ir tyrosine kinase activity
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
EP1971606B1 (en) * 2005-12-05 2013-04-24 GlaxoSmithKline LLC 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
JP5291095B2 (ja) * 2007-06-01 2013-09-18 グラクソスミスクライン エルエルシー イミダゾピリジンキナーゼ阻害剤
US8067409B2 (en) * 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
ES2520991T3 (es) * 2009-05-27 2014-11-12 Abbvie Inc. Inhibidores de pirimidina de la actividad cinasa

Also Published As

Publication number Publication date
EP2435435A1 (en) 2012-04-04
CN102459265A (zh) 2012-05-16
EP2435435B1 (en) 2014-01-29
US8536180B2 (en) 2013-09-17
JP2012528174A (ja) 2012-11-12
ES2453097T3 (es) 2014-04-04
US20100305118A1 (en) 2010-12-02
CA2763624A1 (en) 2010-12-02
WO2010138575A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011012631A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
MX2012013197A (es) Inhibidores de indazol de cinasa.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MY148634A (en) Pyridazinone derivatives
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MX2009010595A (es) Derivados de pirrolopirimidina.
GEP20125564B (en) Pyrimidine derivatives as kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
TN2009000446A1 (en) P70 s6 kinase inhibitors
MX2009013077A (es) Derivados dde benzoxazolona.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MX2010002336A (es) Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MY146989A (en) Kinase inhibitors
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TN2010000131A1 (en) Polo-like kinase inhibitors
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2009007302A (es) Derivados de purina.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration